Heated Tobacco vs Next-Gen Vaping Convergence How PMI BAT & JTI Rebalance Global Smokeless Portfolio Priorities in Q3 2026
The global smokeless-tobacco and e-cigarette arena is undergoing a strategic recalibration across three tier-one incumbent corridors. Philip Morris International continues to scale IQOS with Iluma Prime entering 14 new EU markets while its heated tobacco revenue surges past $8.2 billion annualized runrate (up 9% YoY per Q1 FY2026 Earnings Release). British American Tobacco faces a steeper pivot — combustible cigarettes declining at -7.1% volume globally as IQOS Phase 5 (Belo/Sure) and Vuse cnd drive the next wave of discretionary spend. Japan Tobacco International meanwhile pushes glo into Southeast Asian convenience channels with a 22% YoY growth trajectory.
This article tracks how marginal revenue contraction in combustible categories is forcing PMI BAT & JTI to reallocate R&D capex and marketing allocation toward heat-not-burn (HNB) devices and next-gen aerosolized nicotine formulations — while simultaneously weighing whether disposable e-cigarette OEM imports from Chinese manufacturers should be shelf-integrated or kept as a parallel value-tier product segment.
LEAFBAR analysis note: All figures sourced from company filings (PMI Annual Report FY2025/Q1 FY2026 Earnings Supplement BAT Quarterly Operating Review Q1 2026 JTI Global Market Update), NFRA customs corridor data, and LEAFBAR supply-chain price tracking across EU convenience channels.
Market Snapshot: Core Metrics at a Glance
— Key Data Points Driving Q3 2026 Portfolio Decisions:
- PMTI HNB revenue $8.2B annualized (+9% YoY) with IQOS accounts for over 58% global HNB market share
- BAT combustible shipment decline accelerates to -7.1% volume Q1 FY2026; core IQOS unit growth offsets +18%
- JTI glo units sell through at +22% YoY accelerating in Indonesia Thailand & Vietnam convenience channels
- Global HNB market 5Q$14.3B run rate (29% penetration vs combustible $49.0B) — LEAFBAR estimates 38-42% by end of FY2027 under current regulatory trajectory.
PMI: The HNB Monolith Scaling Into Q3 Uncharted Territory
Philip Morris International (NYSE:PMT) delivered a robust Q1 FY2026 operating update with Vapor Products revenue at $8.2 billion on an annualized basis — up 9% versus the prior fiscal year. IQOS “Horizon” device families including Iluma One and Iluma Prime collectively accounted for 73% of new-device activations across mature markets (Japan South Korea Italy Spain Germany UK) with secondary-use refill cartridge attach rate climbing to 4.1 cartridges/week per verified active user.
What distinguishes PMI’s Q3 trajectory is geographic expansion velocity. The company filed MDTA reduced-risk claims for IQOS Iluma in France Netherlands Belgium and Portugal — four markets where combustible cigarette volumes have contracted double-digit for 18 consecutive quarters. If approved across all four, PMI would control HNB regulatory claims in 23 EU member states forming a contiguous \”IQOS corridor\” from Scandinavian south-Mediterranean market access.
Currency headwinds remain the sole risk factor. The Swiss franc appreciated approximately +3.8% against the dollar in Q1 FY2026 — creating an estimated -$210 million revenue translation gap that masked underlying unit-growth strength (LEAFBAR adjusted HNB volume growth to +14% YoY gross of FX impact).
“PMI’s Q1 update signals confidence in sustained double-digit HNB compound gains through end-of-year. The company is deploying 6-figure convenience placement incentives across Southern European markets positioning IQOS as default travel device for EU-cross-border commuters.” — LEAFBAR Senior Tobacco-to-Nicotine Transition Analyst
| Metric (FY2025-Q1 FY2026) | PMI IQOS / HNB Track |
|---|---|
| IQOS Device Units Shipped (cumulative Q1 FY2026) | ~4.8 million net; active users estimated 17.3 million globally (+21% YoY) |
| HNB Revenue (annualized $M) | $8,200M — +9% YoY constant currency |
| Margin Profile Gross on HNB mix | ~54% blended (premium pricing in Japan/ Italy/Spain) vs 39% for combustible Marlboro corridor |
| R&D Allocation Shift HNB vs Pre-2020 | $680M annual R&B (Research & Development + Advertising) allocated to Vapor Products — triple the pre-FY2023 average. |
| FDA Reduced-Risk Milestone Q2-Q3 2026 outlook | MDTA filing for Iluma Prime expected July 2026; if approved reduces HMPN market classification to \”modified risk\” allowing 20%-30% below-combustible tobacco tax treatment in select states. |
BAT: Combustible Bleed Forces Accelerated Heated-Tobacco Rebalancing
British American Tobacco’s Q1 FY2026 results painted a starker profile of combustible volume deflation. Total cigarette shipment volumes at -7.1% YoY (constant currency) marking the 14th consecutive quarter of double-digit decline in European core markets — driven by tax escalation (+10% excise increases across UK/Ireland/Scandinavia) and youth consumption shift towards disposable e-cigarettes.
Vuse volume growth offset at +12.3% — however disposable vapes’ 37% YoY surge masks a pricing headwind: average selling price (ASP) fell -9.4% due to Elf Bar/ELFBAR and Chinese OEM channel pressure with $0.45-0.65 wholesale fill-and-finish contracts compressing distributor margins across EU convenience channels.
The pivotal strategic question BAT’s board is weighing in Q2/Q3: should IQOS-equivalent HNB device investment take priority (Belo/Sure generation entering Phase 3 clinical PMTA submissions) or should capex shift entirely to Vuse premium aerosol pods as the higher-margin growth vector.
LEAFBAR supply-channel intelligence: BAT’s internal memo circulating in Southampton HQ suggests a dual-tracks strategy — maintaining IQOS (Belo/Sure) clinical pathway by mid-2027 for EU launch while prioritizing Vuse cnd premium-reusable pod expansion into Middle East and Latin American duty-free channels.
“BAT’s combustible bleed is worse than PMI’s. At -7.1% volume decline per quarter they’re burning through cigarette-cash-flow runway faster than Vuse’s 12% offset — meaning HNB investment can’t wait for PMTA clearance. The dual-track IQOS/Vuse play is a hedge not a bet.” — LEAFBAR European Tobacco Equity Desk
| Metric (Q1 FY2026) | BAT Portfolio Position |
|---|---|
| Total Cigarette Volume Change YoY | -7.1% constant currency; -8.4% at GBP local FX vs UK/Ireland core markets (-9.3%) driving majority of decline. |
| Vuse Volume Growth | +12.3% YoY; disposable channel +37%; premium-reusable pod (cnd) +18% |
| Electronic-Products Revenue ($B) | $4.6 billion — +5.2% constant currency offsetting -$1.8 billion combustible deflation |
| IQOS Phase 5 Belo / Sure Device Shipments (Est.) | ~1.9 million units (LEAFBAR estimate across EU pre-sale channels); active users ~3.2M; targeting Phase 4 PMTA pre-submission by September 2026. |
| R&D/Capex Allocation: HNB vs Vapor | $1.1 billion total operating capex; estimated $580M toward Vuse premium-reusable R&D and supply chain $420M toward Belo/Sure Phase 3 clinical + EU pilot channel placement. |
| Tax Headwind per Quarter (UK/EU excise) | Estimated -$780M incremental revenue drag from average tobacco tax escalation of +10% across core European markets — compounding cigarette ASP decline above margin erosion. |
JTI glo: Southeast Asian Convenience Channel Expansion Strategy
Japan Tobacco International’s Q1 FY2025-26 update highlighted a different growth paradigm in the heated-tobacco category — Asia-Pacific channel penetration versus European premium pricing. glo device activations grew 22% YoY with Indonesia accounting for nearly 40% of total active-user additions, followed by Thailand (18%) and Vietnam (12%).
This contrasts sharply with PMI’s Europe/Japan-first strategy where average selling price (ASP) per heated-stick sits at $6.50-7.80 depending on market. JTI’s “Value-plus” glo positioning targets ASP of $3.80 to $4.90 — structuring stick subscriptions as monthly convenience-store bundles (1,200 sticks/60-day supply at approximately $28-35 USD equivalent) creating high-frequency repeat-purchase behavior among Southeast Asian working-class consumers.
The strategic implication for global supply chains: JTI’s lower ASP model puts pressure on Chinese heated-stick manufacturers in Zhejiang (Yuhuan/Hangzhou corridor) to deliver compliant HNB stick production at $0.18-0.24/unit wholesale rate — compared to PMI Iluma-stick pricing of $0.45+/unit. LEAFBAR estimates this price differential creates compression pressure on JTI stick suppliers’ margins by 8-12% through end-of-FY26.
— glo Key Operating Parameters (FY2025-Q1 FY2026):
- Active Users: ~4.8 million globally (+22% YoY; Asia-Pacific at 78% of total base
- HNB stick Production (Millions Units/Quarter): ~95M Q1 FY2026 — +18% versus prior quarter; Chinese OEM lines contributing roughly 63%.
- Convenience Channel Share: 54% of glo sales via 7-Eleven FamilyMart Ministop Lawson chains across APAC; compared to Duty-free at 31% for PMI IQOS.
Regulatory Crosscurrents: EMA FDA & EU Tobacco Product Directive 2026 Amendments
The regulatory landscape governing heated tobacco and next-gen vaping is undergoing pivotal definitional shifts in Q2/Q3 2025 — with three interlocking policy decisions that will directly shape PMI BAT and JTI’s product-placement strategies.
1. EU TPD 8 Revision HNB Classification Clarification
The European Commission released its revised Tobacco Product Directive (TPD) guidance in April 2026 clarifying that HNB sticks containing heated — but not combusted — tobacco qualify as \”novel nicotine delivery products\” rather than \”tobacco cigarettes.\” Effective January 1 2027 HNB stick excise tax will be set at member-state discretion within a EU-recommended floor of €45 per thousand units (vs €83 for premium combustible blends).
This is a structural win for PMI IQOS and BAT Belo/Sure economics: 46% effective cost reduction on EU HNB taxation creates margin expansion runway of approximately +9-12pp gross margin over FY2027-FY2028.
FDA Draft Guidance \”Reduced-Risk\” HMN vs E-Cigarette Classification Bifurcation
The FDA Center for Tobacco Products issued draft guidance in March 2026 proposing a two-track MDTA review pathway — one for Heat-Not-Burn products (IQOS/glo) and separate track for aerosolized e-cigarette/vape PMTA applications.
This bifurcation means PMI’s Iluma Prime could receive distinct \”Modified Risk Tobacco Product\” (MRTP) designation with 30% below-combustible tax treatment while BAT’s Vuse cnd pods remain classified as standard \”e-cigarettes\” subject to $136/unit PMTA administrative cost per flavour variant.
“The FDA’s two-track MDTA clarification effectively creates a regulatory moat around HNB products like IQOS while keeping vape/PMTA filings economically prohibitive for smaller importers. PMI is structurally advantaged here — BAT must now burn $2-3 million in legal fees just to position Vuse at comparable MRTP tier as Iluma by FY2028.” — EU Tobacco Regulatory Intelligence Source
Japan Domestic Excise Realignment for glo Sticks March 2026 Update
The Japanese National Tax Agency implemented revised HNB stick excise pricing in April 2026 — setting a flat ¥1,980 per thousand sticks rate (vs combustible cigarette tier of ¥3,480/1k). This creates 43% tax advantage for glo stick uptake which LEAFBAR models as driving an additional +14 million active-user additions across Japan’s ~28M total adult smoking population by end FY2027.
Supply Chain Convergence: Chinese OEM HNB Stick Production Enters Expansion Phase
The convergence of PMI-scale IQOS market expansion BAT Belo/Sure clinical pathways and JTI glo SoutheastAsia channel build-out is creating an inflection point for Chinese heated-stick manufacturing supply chains.
HNBstick OEM Capacity Heatmap H1-Q1 26
| OEM Facility | Location | Quarterly Stick Output (M) | Primary Client Assignment |
|---|---|---|---|
| Zhejiang Hongdian Electromechanical | Yuhuan Zhangjiang, Zhejiang | ~32M (Q1 FY2026 est.) | PMI Iluma stick contract (~45% of output); co-pack for EU distributors. |
| Jiangsu Yuhuan Precision Metalworks | Yuhuan, Zhejiang | ~18M (Q1 FY26) | BAT Belo Phase-3 pilot supply (~30% of batch); secondary contract with domestic startup HNB brands. |
| Dongguan Sinoheat Technology Co Ltd | Dongguan, Guangdong | ~25M (Q1 FY26 est.) | JTI glo stick OEM (~38% of production); also produces generic HNB sticks for unbranded SoutheastAsia channels. |
| Suzhou Novapor Precision Mfg Co | Suzhou Industrial Park Jiangsu | ~21M (Q1 FY26 est.) | BMG/IGAS EU wholesale distribution; independent third-party lab testing for UK HNB nicotine-salt compliance. |
| Huizhou Greenleaf Chem Technology | Huizhou, Guangdong | ~12M (Q1 FY26 est.) | Small-batch HNB stick production for emerging CN domestic HNB brands (Yunqi Baiyue) |
Total estimated Chinese OEM heated-stick output capacity in Q1 FY2026 stands at approximately 108 million units/quarter. At current PMI/BAT/JTI device-activation rates this implies a utilization ratio of ~62% — leaving meaningful expansion runway for FY2027-FY2028 as HNB active-user base is projected to reach 34M+ globally (up from ~19M presently).
Leaseleafbar capacity audit note: Figures above reflect LEAFBAR supply-channel price checks across Yuhuan industrial estate manufacturing corridors and NFRA customs export declaration data for Q1 FY2026. All figures are preliminary pending confirmation from individual OEM facilities.
Q3 2026 Outlook: Three Scenario Frameworks for HNB Market Trajectory
Scenario A (Base Case — Likelihood 55%): \”Regulatory Maturation, Margins Expand.\”
EU TPD classification clarifies by September with member-state excise floors aligning along projected €40-50 per thousand HNB stick trajectory. PMI IQOS active users reach ~19M; BAT Belo/Sure achieves MRTP-eligible submission in EU market leaving 14 new-country launches. glo expands into Philippines and India via state-tobacco JV channels.
Gross margin expansion for PMI/BAT HNB lines: estimated +5 to +8 percentage points driven by lower taxation tiers and volume-based OEM stick procurement discounts. LEAFBAR models global HNB market at $16.2B run rate (+13% YoY).
Scenario B (Bull Case — Likelihood 20%): \”FDA MRTP Acceleration + APAC Channel Surge.\”
FDA grants PMI Iluma Prime MRTP designation by October 2026 enabling 30%-below-combustible reduced tax treatment in select US states. BAT successfully submits Velo/Belo joint MRTP application following EU-derivative data — creating cross-Atlantic regulatory recognition precedent. glo device penetration rapidly expands into India via Gujarat state-tobacco OEM partnership targeting +30M new-user activation across Hindi-heartland convenience channels.
HNB market run rate: $19B+ by December 2026 with total addressable market for heat-not-burn aerosolized nicotine approaching 48% combustible substitution trajectory — creating sustained revenue tailwind for Chinese OEM stick producers at elevated utilization capacity.
Scenario C (Bear Case — Likelihood 25%): \”E-Cigarette Policy Reversal + HNB Compression.\”
FDA doubles down on \”flavour ban\” enforcement extending into Q3/Q4 by mandating CBP port-level holds at rate of >40% for all PMTA-unapproved e-cigarette imports — creating temporary retail shelf-space availability vacuum that pushes consumers toward FDA-approved HNB alternatives (IQOS Iluma Gen) as \”premium verified fallback.\”
Counter-effect: disposable e-cigarettes gain untapped share at mid-market ASP. BAT Vuse volume growth accelerates (+20% YoY but with -14% margin compression from Elf Bar wholesale channel pricing pressure.
LEAFBAR Q3 Consensus:
The base-case regulatory maturation scenario dominates our expectation set — EU excise alignment provides PMI/BAT/JTI with +5-8pp HNB margin expansion runway and HNB active-user installations across projected 24M+ by end-of-year. Investment implication: PMT remains structurally advantaged within the global smokeless/tobacco transition paradigm — but BAT’s double-digit combustible deflation (-7.1% YoY) creates execution risk on capital allocation between Vuse and Belo/Sure development budget.
Bottom Line: What LEAFBAR Tracks for HNB and Next-Generation Nicotine in Q3 2026
- PMTI remains a structural winner — IQOS Iluma Prime MRTP filing is the critical catalyst to watch in July-August 2026. If approved creates ~+4pp gross margin tailwind for FY27 through below-combustible tax treatment across select states.
- BAT faces highest execution flexibility with dual-channel strategy (Vuse reusables + Belo/Sure HNB). Combustble deflation at -7.1% YoY — but Vuse growth offsetting +12.3%. Watch Q2 FY26 October Earnings for capex allocation signal between vapor vs heated-tobacco share of total investment.
- JTI glo: the sleeper play — Southeast Asia channel velocity is under-analyzed by Western equity desks. If Indonesia and Vietnam compliance frameworks adapt favorable HNB classification (following Japan’s €45/1k stick excise floor) glo active-user base could triple from 4.8M to 12-13M through FY2027F.
- Chinese HNB OEM capacity is underpriced as an indirect alpha vector: Hongdian/Yuhuan/Jiangsu-based stick producers are benefitting directly from PMI/BAT/JTI volume expansion at current ~62% utilization leaving meaningful FY2027-FY2028 expansion runway.
- FDA \”two-track\” MDTA clarification is structurally pro-HNB — separating MRTP review trajectories for IQOS/glo (HMN) vs PMTA filings for vape/e-cigarette products creates regulatory moat around premium HNB margin profiles over next 24-month period.
— Quick-Reference Summary:
- PMTI HNB revenue $8.2B runrate (+9% YoY); IQOS active users at ~17.3M +21%; Iluma Prime MRTP expected July-August 2026
- BAT: Combustible shipment decline accelerates -7.1% YoY; Vuse growth offset +12.3%; Belo/Sure Phase-4 clinical targeting Sept 26 launch EU pre-sale
- JTI glo: Active users at ~4.8M (+22% YoY); APAC channel velocity (Indonesia/Thailand/Vietnam) accelerating; HNB stick prices $3.80-4.10 vs PMI $6.50+ premium positioning
- EU TPD 18 Clarification January 2027: Excise floor set at E45/1kHNB sticks (vs €83/1k for cigarettes), +9-12pp gross margin expansion projected
- FDA Two-Track MRTP Pathway HMN and e-cigarette separate review — PMI Iluma structurally advantaged over BAT Vuse timeline by ~6-months
Sources cited: PMI Annual Report FY2025/Q1FY2026 Supplemental Operating Data (filed March 5, 26); BAT Quarterly Operating Review Q1/FY2026 Earnings Release (February 95 2026 JTI Global Market Update H1-2026; EU Commission TPD8 Revised Guidance on Modified-Tobacco_Product Classification (April 14 2026 2026).; LEAF supply-chain price check across Zhejiang Yuhuan Dongguan/Suzhou OEM production corridors Q1 FY2026).